Itch reduction was evaluated as a key secondary endpoint in randomized, double-blind, placebo-controlled trials: 3 adult trials, 1 trial in adolescents (12-17 years of age), 1 trial in children (6-11 years of age), 1 trial in infants to preschoolers (6 months to 5 years of age) with uncontrolled moderate-to-severe atopic dermatitis, and 1 trial in atopic dermatitis patients (12 years and older) with uncontrolled moderate-to-severe hand and/or foot involvement.^1,2 Click here for additional clinical trial design information.

Itch reduction with DUPIXENT was rapid and sustained in adults at 52 weeks. In SOLO 1, a significantly greater proportion of adult patients had improvement on the Peak Pruritus NRS score vs placebo (defined as at least a 4-point improvement) as early as Week 2 (9% of DUPIXENT patients achieved ≥4-point reduction in NRS score at Week 2 vs 3% with placebo [P=0.0097]).^1,2

• 41% of adult patients achieved a ≥4-point improvement in the Peak Pruritus NRS with DUPIXENT at Week 16 in SOLO 1 vs 12% with placebo^1,3
• 36% of adult patients achieved a ≥4-point improvement in the Peak Pruritus NRS with DUPIXENT at Week 16 in SOLO 2 vs 10% with placebo^1,3

In addition, in CHRONOS^1,4:

• 59% of adult patients achieved a ≥4-point improvement in the Peak Pruritus NRS with DUPIXENT + TCS at Week 16 vs 20% in placebo + TCS
• 51% of adult patients experienced sustained itch reduction at 52 weeks with DUPIXENT + TCS in CHRONOS vs 13% with placebo + TCS

A greater proportion of adolescents treated with DUPIXENT and children treated with DUPIXENT + TCS achieved an improvement in the Peak Pruritus NRS compared with placebo (defined as ≥4-point improvement) and as early as Week 4 in adolescents (22% with DUPIXENT vs 5% with placebo; nominal P<0.001).⁵

• 37% of adolescent patients treated with DUPIXENT achieved a ≥4-point improvement in the Peak Pruritus NRS at Week 16 vs 5% with placebo (P<0.001)^1,6

• 54% of children treated with DUPIXENT 300 mg Q4W + TCS (<30 kg) achieved a ≥4-point improvement in the Peak Pruritus NRS at Week 16 vs 12% with placebo + TCS at Week 16^1,7
• 61% of children treated with DUPIXENT 200 mg Q2W + TCS (≥30 kg) achieved a ≥4-point improvement in the Peak Pruritus NRS at Week 16 vs 13% with placebo + TCS at Week 16^1,7

A greater proportion of infants to preschoolers treated with DUPIXENT + TCS had an improvement in Worst Scratch/Itch NRS compared with placebo (defined as ≥4-point improvement) at Week 3 (48% with DUPIXENT + TCS vs 9% with placebo + TCS).^1,2

• 48% of patients treated with DUPIXENT + TCS achieved ≥4-point improvement in Worst Scratch/Itch NRS vs 9% with placebo + TCS at Week 16, P<0.0001

A greater proportion of atopic dermatitis patients aged 12+ years with uncontrolled moderate-to-severe hand and/or foot involvement treated with DUPIXENT achieved an improvement in the hand and foot Peak Pruritus NRS at Week 16 compared with placebo (defined as ≥4-point improvement).^1,2

• 52% of adolescent patients treated with DUPIXENT achieved a ≥4-point improvement in hand and foot Peak Pruritus NRS at Week 16 vs 14% with placebo (P<0.0001)